SHR-1209
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Familial Hypercholesterolemia
Conditions
Familial Hypercholesterolemia
Trial Timeline
Sep 1, 2020 → Aug 31, 2021
NCT ID
NCT04455581About SHR-1209
SHR-1209 is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Familial Hypercholesterolemia. The current trial status is unknown. This product is registered under clinical trial identifier NCT04455581. Target conditions include Familial Hypercholesterolemia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05370950 | Phase 1 | Completed |
| NCT04455581 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Familial Hypercholesterolemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Bromocriptine Mesilate + Placebos | Towa Pharmaceutical | Phase 1/2 | 40 |
| SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placebo | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Rosuvastatin 20mg + Placebo | AstraZeneca | Phase 3 | 77 |
| rosuvastatin calcium + rosuvastatin calcium + rosuvastatin calcium | AstraZeneca | Phase 3 | 77 |
| Rosuvastatin + Placebo | AstraZeneca | Phase 3 | 77 |
| Rosuvastatin 20mg | AstraZeneca | Phase 3 | 77 |
| AZD0780 + Placebo | AstraZeneca | Phase 3 | 77 |
| Anacetrapib + Placebo for anacetrapib | Merck | Phase 3 | 77 |
| Statins and Ezetimibe | Merck | Pre-clinical | 23 |
| Comparator: niacin (+) laropiprant (MK0524A) + Comparator: placebo | Merck | Phase 3 | 77 |
| MK-0524A + MK-0524A | Merck | Phase 1 | 33 |
| Enlicitide Decanoate + Placebo | Merck | Phase 2/3 | 65 |
| Inclisiran + Placebo | Novartis | Phase 3 | 77 |
| DFV890 | Novartis | Phase 2 | 52 |
| Canakinumab | Novartis | Phase 2 | 52 |
| Inclisiran Sodium for injection + Placebo + Placebos | Novartis | Phase 3 | 77 |
| LCQ908 + Placebo | Novartis | Phase 3 | 77 |
| Inclisiran | Novartis | Phase 3 | 77 |
| Inclisiran + Placebo | Novartis | Phase 3 | 77 |
| Fluvastatin | Novartis | Phase 3 | 77 |